Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

Multiple Cancer Types

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Neuroblastoma (Pediatrics), Pediatrics
III
Kitko, Carrie
NCT03126916
COGANBL1531

Chemotherapy Levels in the Eyes of Patients with Retinoblastoma

Retinoblastoma (Pediatrics)

Retinoblastoma (Pediatrics)
N/A
Daniels, Anthony
VICCREACH17106

Dexamethasone, Lenalidomide, Carfilzomib, and Daratumumab in Treating Participants with Multiple Myeloma

Multiple Myeloma

This phase II trial studies how well dexamethasone, lenalidomide, carfilzomib, and daratumumab work in treating participants with multiple myeloma. Drugs used in chemotherapy, such as dexamethasone, lenalidomide, and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may interfere with the ability of cancer cells to grow and spread. Giving dexamethasone, lenalidomide, carfilzomib, and daratumumab may work better in treating participants with multiple myeloma.
Multiple Myeloma
II
Cornell, Robert
NCT03224507
VICCPCL1871

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: